TrialNet researchers are testing low-dose anti-thymocyte globulin (ATG), an immunotherapy, to find out if it can delay or prevent type 1 diabetes (T1D) in people at high risk of clinical diagnosis (Stage 3) within two years. 

DECA Executive Director Terry Ackley, and his wife, Carol, volunteered at Camp Seale Harris for several years before he was hired as the Camp’s executive director in 1995. He served in that role until joining DECA in 2012. Pictured here: Terry and Carol (right) with daughter, Emily (left), son-in-law, Patrick, and granddaughter, Vivienne.

Findings from the TrialNet Abatacept Prevention Study, published online in Diabetes Care, provide important new information about how abatacept impacts type 1 diabetes (T1D) progression and suggest direction for additional research.

The Gilchrist family loves to read. When Emmie (pictured bottom right) was first diagnosed with T1D at age 4, Amanda asked her school librarian for all the books that had characters with T1D. There weren’t a lot. Now, when Amanda and Emmie meet authors (in person or online), they ask them to put characters with T1D into their next stories.

TrialNet Chair Kevan C. Herold, MD, reflects on advances in type 1 diabetes research and the need to continue testing promising treatments.

Dear TrialNet Family,

As we near the release of findings from the Abatacept Prevention Study, two participants share how their experiences in TrialNet research helped shape their futures.

Meet Orlando Brown, Jr.: You may recognize the Kansas City Chiefs offensive tackle, also known as “Zeus”. It’s evident why, especially on the gridiron. More than 350 pounds of superhuman muscle and momentum sprinting downfield, Orlando inherited the name and strength of his father, also an NFL hero.

Landmark findings from TrialNet research were instrumental in the Food and Drug Administration’s (FDA) November 17, 2022 approval of the first drug to delay type 1 diabetes (T1D) in people at risk.

TrialNet conducted the clinical study that discovered the immunotherapy drug teplizumab could delay T1D for 2+ years.

Meet Owen & Ella: As another modular plate locks into place Owen does a fist bump. Whenever he adds a new piece to enhance the armor on his super suit he loves making the pieces snap together, just like his favorite Legos. Always calm under pressure, Ella goes over detailed schematics for their next TrialNet T1D Heroes Academy mission.

Meet Citlaly & Maria: Super siblings united! Wind and water follow their command as Citlaly and Maria roam through downtown San Jose. Citlaly’s frisbee whistles as it whips through the air in a long arc circling the skyscrapers. In between TrialNet T1D Heroes Academy missions and studying to be a nurse, Maria tests her ability to manipulate water from the city fountains.